Proprietary AI analyst is now available
- Public Comps
- Nextbiomedical Co
Nextbiomedical Co Valuation Multiples
Discover revenue and EBITDA valuation multiples for Nextbiomedical Co and similar public comparables like S Biomedics, Heartseed, Fulcrum Therapeutics, Foghorn Therapeutics and more.
Nextbiomedical Co Overview
About Nextbiomedical Co
Nextbiomedical Co Ltd is an bio-solution company. The company develops and commercializes therapeutic agents for treating diseases based on polymer and drug delivery system technology. The company has developed products that include endoscopic hemostatic agents, vascular embolic microspheres, and others.
Founded
2014
HQ

Employees
N/A
Website
Financials (LTM)
EV
$205M
Valuation Multiples
Start free trialNextbiomedical Co Financials
Nextbiomedical Co reported last 12-month revenue of $13M and negative EBITDA of ($634K).
In the same LTM period, Nextbiomedical Co generated $9M in gross profit, ($634K) in EBITDA losses, and had net loss of ($969K).
Revenue (LTM)
Nextbiomedical Co P&L
In the most recent fiscal year, Nextbiomedical Co reported revenue of $11M and EBITDA of $376K.
Nextbiomedical Co is unprofitable as of last fiscal year, with gross margin of 69%, EBITDA margin of 3%, and net margin of (1%).
Financial data powered by Morningstar, Inc.
Nextbiomedical Co Stock Performance
Nextbiomedical Co has current market cap of $222M, and enterprise value of $205M.
Market Cap Evolution
Nextbiomedical Co's stock price is $27.35.
Nextbiomedical Co share price decreased by 1.1% in the last 30 days, and by 12.3% in the last year.
Nextbiomedical Co has an EPS (earnings per share) of $-0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $205M | $222M | -2.4% | -1.1% | -45.1% | -12.3% | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNextbiomedical Co Valuation Multiples
Nextbiomedical Co trades at 16.2x EV/Revenue multiple, and (323.8x) EV/EBITDA.
EV / Revenue (LTM)
Nextbiomedical Co Financial Valuation Multiples
As of June 5, 2026, Nextbiomedical Co has market cap of $222M and EV of $205M.
Nextbiomedical Co has a P/E ratio of (229.4x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Nextbiomedical Co Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Nextbiomedical Co Margins & Growth Rates
Nextbiomedical Co grew revenue by 39% but EBITDA decreased by 558% in the last fiscal year.
In the most recent fiscal year, Nextbiomedical Co reported gross margin of 69%, EBITDA margin of 3%, and net margin of (1%).
Nextbiomedical Co Margins
Nextbiomedical Co Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Nextbiomedical Co Operational KPIs
Nextbiomedical Co's Rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nextbiomedical Co's Rule of X is 89% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Nextbiomedical Co Competitors
Nextbiomedical Co competitors include S Biomedics, Heartseed, Fulcrum Therapeutics, Foghorn Therapeutics, Voyager Therapeutics, LENZ Therapeutics, Camp4 Therapeutics, Whitehawk Therapeutics, Tetratherix and Starpharma.
Most Nextbiomedical Co public comparables operate across Biopharmaceuticals, BioTech, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 20.5x | - | (102.3x) | - | |||
| 9.5x | 14.9x | 85.9x | - | |||
| - | - | 1.2x | 1.4x | |||
| 2.5x | 2.7x | (1.0x) | (0.9x) | |||
| 2.8x | 2.7x | (0.9x) | (0.9x) | |||
| (1.7x) | (1.7x) | 0.4x | 0.3x | |||
| 37.0x | 28.5x | (2.6x) | (1.7x) | |||
| 10.1x | 17.7x | (3.5x) | - | |||
This data is available for Pro users. Sign up to see all Nextbiomedical Co competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Nextbiomedical Co
| When was Nextbiomedical Co founded? | Nextbiomedical Co was founded in 2014. |
| Where is Nextbiomedical Co headquartered? | Nextbiomedical Co is headquartered in South Korea. |
| Is Nextbiomedical Co publicly listed? | Yes, Nextbiomedical Co is a public company listed on Korea Exchange. |
| What is the stock symbol of Nextbiomedical Co? | Nextbiomedical Co trades under 389650 ticker. |
| When did Nextbiomedical Co go public? | Nextbiomedical Co went public in 2024. |
| Who are competitors of Nextbiomedical Co? | Nextbiomedical Co main competitors include S Biomedics, Heartseed, Fulcrum Therapeutics, Foghorn Therapeutics, Voyager Therapeutics, LENZ Therapeutics, Camp4 Therapeutics, Whitehawk Therapeutics, Tetratherix, Starpharma. |
| What is the current market cap of Nextbiomedical Co? | Nextbiomedical Co's current market cap is $222M. |
| What is the current revenue of Nextbiomedical Co? | Nextbiomedical Co's last 12 months revenue is $13M. |
| What is the current revenue growth of Nextbiomedical Co? | Nextbiomedical Co revenue growth (NTM/LTM) is 50%. |
| What is the current EV/Revenue multiple of Nextbiomedical Co? | Current revenue multiple of Nextbiomedical Co is 16.2x. |
| Is Nextbiomedical Co profitable? | No, Nextbiomedical Co is not profitable. |
| What is the current EBITDA of Nextbiomedical Co? | Nextbiomedical Co has negative EBITDA and is not profitable. |
| What is Nextbiomedical Co's EBITDA margin? | Nextbiomedical Co's last 12 months EBITDA margin is (5%). |
| What is the current EV/EBITDA multiple of Nextbiomedical Co? | Current EBITDA multiple of Nextbiomedical Co is (323.8x). |
| What is the current FCF of Nextbiomedical Co? | Nextbiomedical Co's last 12 months FCF is ($3M). |
| What is Nextbiomedical Co's FCF margin? | Nextbiomedical Co's last 12 months FCF margin is (20%). |
| What is the current EV/FCF multiple of Nextbiomedical Co? | Current FCF multiple of Nextbiomedical Co is (81.8x). |
| How many companies Nextbiomedical Co has acquired to date? | Nextbiomedical Co hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Nextbiomedical Co has invested to date? | Nextbiomedical Co hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Nextbiomedical Co
Lists including Nextbiomedical Co
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.